Shuttle Pharmaceuticals Holdings, Inc. - common stock (SHPH)

ROCKVILLE, MD / ACCESS Newswire / October 22, 2025 / Every generation has its frontier. For the last century, medicine's remained molecular: genes, proteins, receptors, the invisible mechanics of life. Today, that frontier is shifting again. The next wave isn't about what we can see under a microscope. It's about what we can teach a machine to see for us.

ROCKVILLE, MD / ACCESS Newswire / October 22, 2025 / Artificial intelligence has reshaped nearly every industry, but drug discovery has always been its toughest proving ground. Molecules don't follow patterns; they twist, bind, and defy prediction, humbling even the smartest algorithms.

ROCKVILLE, MD / ACCESS Newswire / October 21, 2025 / Radiation therapy has always been the heavyweight of cancer treatment. It works, but it's a brute. It blasts cancer cells, hoping the good ones can withstand the damage. For decades, that was the tradeoff. Precision meant power, and power meant pain, along with a whole lot of side effects. But what if the next evolution of radiation wasn't about turning up the dose, but about turning up the intelligence?

Rockville, Maryland--(Newsfile Corp. - October 21, 2025) - Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) ("Shuttle" or the "Company") today announced...

As market momentum builds, five stocks across diverse sectors are showing signs of significant movement, approaching crucial technical trendlines that could set the stage for breakout performances. These companies have captured investor attention as they align near important resistance levels. Each company brings sector-specific innovation, from tech advancements in mmWave and biometric authentication to cutting-edge oncology therapies, positioning them to potentially drive gains as they test these key thresholds.

Trading volume and share price for BFRG took significant leaps forward on news the digital biopharmaceutical company will partner with Johns Hopkins University.